Stanway (pictured) said commercial concerns were the most likely reason for Novartis to get cold feet on the project. He told pharmaphorum in an interview: “Some commentators say they may be ...

The comedian, actress, and breast cancer survivor joins singer, actress, and advocate Hailee Steinfeld in the Novartis commercial 'Your Attention, Please,' which boldly addresses society’s ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pharmaceutical company Novartis is laying off more than 400 employees at its East Hanover facility as part of a restructuring effort tied to shifts in its cardiovascular drug portfolio. Novartis ...

Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...

Novartis signed on for its space at the Fifth Avenue building between West 39th and West 40th streets in January 2023, as Commercial Observer previously reported. It represented the company’s first ...

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...

The Swiss pharma giant – which has its U.S. headquarters in East Hanover – said it aims to encourage football fans to "proactively manage their health." ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...